ARS Pharmaceuticals (SPRY) Stock Chart & Stock Price History $17.91 +0.35 (+2.02%) As of 11:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARS Pharmaceuticals Stock Price Performance The ARS Pharmaceuticals (SPRY) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 57.97%, with a year-to-date return of 69.80%. In the past month, the stock has increased 18.17%, reflecting recent market activity. As of the latest close, ARS Pharmaceuticals traded at $17.56 with a market cap of $1.72 billion and volume of 972,831 shares. Receive SPRY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+1.27%1 Month Performance+18.17%3 Month Performance+20.39%Year-To-Date Performance+69.80%1 Year Performance+57.97% SPRY Stock Chart for Wednesday, July, 16, 2025 SPRY Chart by TradingView ARS Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/15/2025$17.90$17.56-1.90%$18.00$17.19972,831 shs$1.72 billion07/14/2025$17.69$17.90+1.19%$18.22$17.61926,501 shs$1.76 billion07/11/2025$17.98$17.69-1.61%$18.05$17.461.11 million shs$1.74 billion07/10/2025$17.90$17.98+0.45%$18.05$17.291.43 million shs$1.77 billion07/09/2025$16.95$17.90+5.60%$17.94$16.961.21 million shs$1.76 billion07/08/2025$17.09$16.95-0.82%$17.44$16.401.30 million shs$1.66 billion07/07/2025$16.49$17.09+3.67%$17.90$16.441.66 million shs$1.68 billion07/04/2025$16.49$16.49$16.81$16.15881,491 shs$1.62 billion07/03/2025$16.75$16.49-1.58%$16.81$16.15881,491 shs$1.62 billion07/02/2025$16.09$16.75+4.10%$16.76$15.751.28 million shs$1.65 billion Get the Latest News and Ratings for SPRY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/01/2025$17.45$16.09-7.79%$17.41$16.001.86 million shs$1.58 billion06/30/2025$18.20$17.45-4.12%$18.50$16.163.16 million shs$1.71 billion06/27/2025$18.08$18.20+0.66%$18.90$18.113.88 million shs$1.79 billion06/26/2025$17.26$18.08+4.75%$18.21$17.271.80 million shs$1.78 billion06/25/2025$16.78$17.26+2.86%$17.54$16.851.40 million shs$1.70 billion06/24/2025$16.57$16.78+1.27%$17.50$16.301.94 million shs$1.65 billion06/23/2025$15.80$16.57+4.87%$16.59$15.671.41 million shs$1.63 billion06/20/2025$15.91$15.80-0.69%$16.11$15.451.34 million shs$1.55 billion06/19/2025$15.91$15.91$16.23$14.802.73 million shs$1.56 billion06/18/2025$14.82$15.91+7.35%$16.23$14.802.73 million shs$1.56 billion06/17/2025$15.16$14.82-2.24%$15.12$14.77983,659 shs$1.46 billion06/16/2025$15.39$15.16-1.49%$15.68$14.861.44 million shs$1.49 billion Related Companies GRFS Stock Chart TGTX Stock Chart NUVL Stock Chart LNTH Stock Chart RYTM Stock Chart AXSM Stock Chart TLX Stock Chart CRSP Stock Chart PCVX Stock Chart CYTK Stock Chart Receive SPRY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:SPRY) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredMajor Rollout of Social Security X?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRY Stock Alerts